ReviewFrontiers in aging2021
Estrogen Receptor and Vascular Aging.
Review in Frontiers in aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Gender-Specific Associations Between Sex Hormones and Cardiovascular Disease: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2026Pooled it
- Aromatase enzyme: Paving the way for exploring aromatization for cardio-renal protection.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Pooled it
- Effect of Hormone Therapy on Lipoprotein Subfractions in Early and Late Postmenopausal Women.The Journal of clinical endocrinology and metabolism · 2025Trial
- Elevated cardiovascular risk associated with hormone replacement therapy: A comprehensive analysis of reproductive factors and atherosclerotic cardiovascular disease outcomes in the UK Biobank cohort.Acta obstetricia et gynecologica Scandinavica · 2026Article
- Sex differences in vascular function among individuals with heart failure: a systematic review.International journal of cardiology. Heart & vasculature · 2026Review
- Endothelial Estrogen Receptor Alpha Inhibits Plaque Inflammation in Both Sexes.Circulation research · 2026Article
- Is endothelial dysfunction induced by aromatase inhibitors reversible after treatment?Breast cancer research and treatment · 2026Article
- Exploring the relationship between reproductive aging, arterial stiffness, and cardiorespiratory fitness in women after menopause.Physiological reports · 2026Article
- Pharmacotherapeutic considerations of selective estrogen receptor modulators for vascular protection.Frontiers in pharmacology · 2026Review
- COVID-19 associated CKM syndrome progression in diabetic patients is linked to pancreatic beta cell dysfunction, rather than RASi use: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Sex-specific body fat distribution predicts cardiovascular ageing.European heart journal · 2025Article
- Sex steroid hormones drive dimorphic responses in GDF15-deficient mouse models of cardiometabolic diseases.Scientific reports · 2025Article
- Article
- Mechanisms of endothelial senescence and vascular aging.Biogerontology · 2025Review
- Dissecting endothelial cell heterogeneity with new tools.Cell regeneration (London, England) · 2025Review
- Chronic treatment with photobiomodulation decreases blood pressure and improves endothelial function in ovariectomized rats.Lasers in medical science · 2025Article
- Review
- Unraveling the metabolic pathways between atherosclerosis and sarcopenia.Frontiers in endocrinology · 2025Review
- Macrophages and osteoclasts: similarity and divergence between bone phagocytes.Frontiers in immunology · 2025Review
- Estimating the societal cost of type 2 diabetes in Malmö, Sweden: a register-based cost analysis.Frontiers in clinical diabetes and healthcare · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases remain an age-related pathology in both men and women. These pathologies are 3-fold more frequent in men than in women before menopause, although this difference progressively decreases after menopause. The vasculoprotective role of estrogens are well established before menopause, but the consequences of their abrupt decline on the cardiovascular risk at menopause remain debated. In this review, we will attempt to summarize the main clinical and experimental studies reporting the protective effects of estrogens against cardiovascular diseases, with a particular focus on atherosclerosis, and the impact of aging and estrogen deprivation on their endothelial actions. The arterial actions of estrogens, but also part of that of androgens through their aromatization into estrogens, are mediated by the estrogen receptor (ER)α and ERβ. ERs belong to the nuclear receptor family and act by transcriptional regulation in the nucleus, but also exert non-genomic/extranuclear actions. Beside the decline of estrogens at menopause, abnormalities in the expression and/or function of ERs in the tissues, and particularly in arteries, could contribute to the failure of classic estrogens to protect arteries during aging. Finally, we will discuss how recent insights in the mechanisms of action of ERα could contribute to optimize the hormonal treatment of the menopause.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.